Want to see IN:VENUSREM full AI Analyst Report?

Venus Remedies Limited (VENUSREM) Price & Analysis

1 Followers

VENUSREM Stock Chart & Stats

₹1650.60

-₹77.00(-4.67%)

At close: Jul 27 4:00 PM EDT

₹1650.60

-₹77.00(-4.67%)

Day’s Range― - ―

52-Week Range₹423.70 - ₹2,043.15

Previous CloseN/A

Volume69.99K

Average Volume (3M)2.33K

Market Cap

₹20.94B

Enterprise Value₹10.13K

Total Cash (Recent Filing)₹1.04B

Total Debt (Recent Filing)₹124.10M

Price to Earnings (P/E)18.2

Beta0.75

Next Earnings

Nov 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)76.91

Shares Outstanding13,366,988

10 Day Avg. Volume2,529

30 Day Avg. Volume2,330

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)1.65

Price to Sales (P/S)1.42

P/FCF Ratio9.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)39.9

Revenue Forecast (FY)₹828.20M

Bulls Say, Bears Say

Bulls Say

Diversified Revenue ModelVenus Remedies derives revenues from multiple channels—branded formulations, contract/B2B manufacturing, exports and hospital/critical-care tenders. This multi-channel model reduces single-channel dependence, provides alternate growth levers and supports more stable mid‑term revenue as different streams mature at different paces.

Improved Cash GenerationOperating and free cash flow improved substantially in 2026, materially boosting internal funding capacity. Strong cash generation enhances the company's ability to fund capex, invest in registrations/exports, reduce leverage or support strategic initiatives over the next several quarters, strengthening structural financial resilience.

Conservative Balance SheetReportedly low leverage and steady equity growth provide financial flexibility to absorb shocks and pursue growth without aggressive external financing. A conservatively positioned balance sheet supports durable investment in product registrations, capacity and working capital, and lowers refinancing risk in the medium term.

Bears Say

Margin VolatilityMargins have shown material fluctuation historically and the lack of clear 2026 margin detail clouds whether the recent earnings surge is sustainable. For a pharma manufacturer, mix shifts, pricing and input-cost pressure can quickly reverse profit gains, reducing predictability of future earnings and cash flow.

Choppy Cash ConversionDespite a strong 2026, prior years show operating cash flow lagging reported net income and uneven free cash flow. Persistent variability in cash conversion suggests working-capital and capex cycles can strain liquidity and complicate consistent reinvestment or deleveraging plans across multiple quarters.

Tender/contract Concentration RiskSignificant exposure to hospital tenders and contractual B2B supply creates structural revenue sensitivity to competitive tender outcomes and partner concentration. Such institutional procurement dynamics can cause abrupt volume and pricing swings, reducing long‑term visibility on revenue and margin sustainability.

Venus Remedies Limited News

Venus Remedies Publishes 37th AGM Notice in Compliance Filing

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited has notified the stock exchange...

9d ago

Venus Remedies Clears FY26 Results, Declares Final Dividend and Strengthens Governance

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited reported its audited financial results...

2M ago

Venus Remedies Posts FY26 Results, Sets AGM and Dividend, Strengthens Governance

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited reported its financial results for...

2M ago

Venus Remedies Declares Final Dividend and Sets August Virtual AGM

The latest update is out from Venus Remedies Limited ( ($IN:VENUSREM) ). Venus Remedies Limited has reported its...

2M ago

Venus Remedies Opens Special Window for Physical Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited has notified the stock exchange...

3M ago

Venus Remedies Alerts Shareholders to Special Window for Physical Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) just unveiled an update. Venus Remedies has notified stock exchanges that it...

5M ago

Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has notified the...

6M ago

Venus Remedies Closes Trading Window Ahead of December 2025 Results

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited has announced that, in accordance...

8M ago

Venus Remedies Opens Special Window for Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has announced the opening of...

8M ago

Venus Remedies Completes AMR Licensing Milestones with Final Payment

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has successfully completed all commercial...

8M ago

VENUSREM FAQ

What was Venus Remedies Limited’s price range in the past 12 months?

Venus Remedies Limited lowest stock price was ₹423.70 and its highest was ₹2043.15 in the past 12 months.

What is Venus Remedies Limited’s market cap?

Venus Remedies Limited’s market cap is ₹20.94B.

When is Venus Remedies Limited’s upcoming earnings report date?

Venus Remedies Limited’s upcoming earnings report date is Nov 14, 2026 which is in 101 days.

How were Venus Remedies Limited’s earnings last quarter?

Venus Remedies Limited released its earnings results on Jul 20, 2026. The company reported ₹17.184 earnings per share for the quarter, beating the consensus estimate of N/A by ₹17.184.

Is Venus Remedies Limited overvalued?

According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Venus Remedies Limited pay dividends?

Venus Remedies Limited pays a Notavailable dividend of ₹10 which represents an annual dividend yield of N/A. See more information on Venus Remedies Limited dividends here

What is Venus Remedies Limited’s EPS estimate?

Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Venus Remedies Limited have?

Venus Remedies Limited has 13,366,988 shares outstanding.

What happened to Venus Remedies Limited’s price movement after its last earnings report?

Venus Remedies Limited reported an EPS of ₹17.184 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.564%.

Which hedge fund is a major shareholder of Venus Remedies Limited?

Currently, no hedge funds are holding shares in IN:VENUSREM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Venus Remedies Limited

Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spectrum of therapeutic areas, including treatments for pain and fever, diabetes, bacterial infections, cardiovascular conditions, gastrointestinal disorders, neurological ailments, and oncology. Additionally, it provides solutions for respiratory health, skin and wound care, stress management, and urological issues, alongside essential vitamins, minerals, and nutritional supplements. Venus Remedies is also active in the field of antimicrobial resistance, offering specialized products, and it supplies disinfectants and hand sanitizers. Furthermore, the firm maintains a distinct line of herbal products and offers hormones and iron supplements. Established in 1989, Venus Remedies Limited operates from its headquarters in Panchkula, India.